组织因子途径抑制物的研究进展  

The research progress of tissue factor pathway inhibitor

作　　者：曹翔宇 吴俊[1] Cao Xiangyu;Wu Jun(Beijing jishuitanhospital clinical laboratory,Beijing100035,China)

机构地区：[1]北京积水潭医院检验科,北京100035

出　　处：《中华检验医学杂志》2022年第10期1005-1009,共5页Chinese Journal of Laboratory Medicine

摘　　要：组织因子途径抑制物(TFPI)是组织因子介导的外源性凝血途径的主要抑制物,主要来源于微血管内皮细胞。近年研究发现,TFPI在血友病、脓毒症、抗磷脂综合征、静脉血栓栓塞等疾病中发挥作用,并且通过抗凝机制参与疾病的发生和发展。目前有多种方法检测TFPI的来源、含量及功能,有助于临床疾病的诊断和治疗。Tissue factor pathway inhibitor(TFPI)is a major inhibitor of tissue factor-mediated extrinsic coagulation pathway,mainly derived from microvascular endothelial cells.Recent studies have found that TFPI plays a role in hemophilia,sepsis,antiphospholipid syndrome,venous thromboembolism and other diseases,and participates in the occurrence and development of diseases through anticoagulation mechanism.At present,there are many methods to detect the source,content and function of TFPI,which are helpful for the diagnosis and treatment of clinical diseases.

关 键 词：组织因子途径抑制物 抗凝 检测方法 出凝血疾病 

分 类 号：R363[医药卫生—病理学]